Medrobotics gets expanded CE mark nod for its robot-assisted surgical device

The European Union has given its CE mark approval to Medrobotics’ Flex robot-assisted surgery system, expanding the device’s indication to include colorectal procedures. 

The company, which is based in Raynham, MA, touts itself as the first in its field to offer minimally invasive and steerable robotic products for colorectal uses.

“CE Mark for colorectal procedures is significant since it expands the number of patients who can be treated with the Flex robotic system and provides a true platform technology that multiple hospital departments can use,” Samuel Straface, Medrobotics’ CEO, said in a statement. “When combined with the unrivaled mobility of the system, European otolaryngology and colorectal surgeons can now perform minimally invasive surgery through the body’s natural orifices, offering the potential for truly scarless surgeries.”

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Earlier this year, the Flex system won Best-in-Show honors at the Medical Design Excellence Awards. The robot-assisted surgical platform is designed to be affordable, easy-to-use and highly mobile for hospitals and surgeons when performing minimally invasive treatments, the company said.

In November last year, Medrobotics raised $25 million just months after gaining FDA 510(k) clearance for transoral procedures.

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.